Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases

Lucia Saidenberg; Arnaldo A. Arbini; Gregg J. Silverman; Itay Lotan; Gary Cutter; Ilya Kister

doi:10.1016/j.msard.2022.103830

Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases

Lucia Saidenberg^*, Arnaldo A. Arbini, Gregg J. Silverman, Itay Lotan, Gary Cutter, Ilya Kister

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

16 Scopus citations

Abstract

This retrospective, single-center study aimed to characterize and compare the kinetics of B-cell reemergence following anti-CD20 infusion (anti-CD20i) in African American (AA) and white patients with MS or NMOSD. In a logistic regression model that included race, time since anti-CD20i, body mass index, and diagnosis, only AA race (p=0.01) and time since anti-CD20i (p=0.0003) were significant predictors of B-cell repletion. However, B-cell subset composition was similar between AA and white patients with detectable CD19+ B-cell counts. These findings highlight the importance of including a diverse study population in future studies of anti-CD20 therapies.

Original language	English
Article number	103830
Journal	Multiple Sclerosis and Related Disorders
Volume	63
DOIs	https://doi.org/10.1016/j.msard.2022.103830
State	Published - Jul 2022
Externally published	Yes

Keywords

anti-CD20
b-cell repletion
multiple sclerosis
neuromyelitis optica
ocrelizumab
race
rituximab

Access to Document

10.1016/j.msard.2022.103830

Cite this

@article{6649c9c3b940497f876c9de5bb9ece2f,

title = "Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases",

abstract = "This retrospective, single-center study aimed to characterize and compare the kinetics of B-cell reemergence following anti-CD20 infusion (anti-CD20i) in African American (AA) and white patients with MS or NMOSD. In a logistic regression model that included race, time since anti-CD20i, body mass index, and diagnosis, only AA race (p=0.01) and time since anti-CD20i (p=0.0003) were significant predictors of B-cell repletion. However, B-cell subset composition was similar between AA and white patients with detectable CD19+ B-cell counts. These findings highlight the importance of including a diverse study population in future studies of anti-CD20 therapies.",

keywords = "anti-CD20, b-cell repletion, multiple sclerosis, neuromyelitis optica, ocrelizumab, race, rituximab",

author = "Lucia Saidenberg and Arbini, {Arnaldo A.} and Silverman, {Gregg J.} and Itay Lotan and Gary Cutter and Ilya Kister",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jul,

doi = "10.1016/j.msard.2022.103830",

language = "אנגלית",

volume = "63",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases

AU - Saidenberg, Lucia

AU - Arbini, Arnaldo A.

AU - Silverman, Gregg J.

AU - Lotan, Itay

AU - Cutter, Gary

AU - Kister, Ilya

PY - 2022/7

Y1 - 2022/7

N2 - This retrospective, single-center study aimed to characterize and compare the kinetics of B-cell reemergence following anti-CD20 infusion (anti-CD20i) in African American (AA) and white patients with MS or NMOSD. In a logistic regression model that included race, time since anti-CD20i, body mass index, and diagnosis, only AA race (p=0.01) and time since anti-CD20i (p=0.0003) were significant predictors of B-cell repletion. However, B-cell subset composition was similar between AA and white patients with detectable CD19+ B-cell counts. These findings highlight the importance of including a diverse study population in future studies of anti-CD20 therapies.

AB - This retrospective, single-center study aimed to characterize and compare the kinetics of B-cell reemergence following anti-CD20 infusion (anti-CD20i) in African American (AA) and white patients with MS or NMOSD. In a logistic regression model that included race, time since anti-CD20i, body mass index, and diagnosis, only AA race (p=0.01) and time since anti-CD20i (p=0.0003) were significant predictors of B-cell repletion. However, B-cell subset composition was similar between AA and white patients with detectable CD19+ B-cell counts. These findings highlight the importance of including a diverse study population in future studies of anti-CD20 therapies.

KW - anti-CD20

KW - b-cell repletion

KW - multiple sclerosis

KW - neuromyelitis optica

KW - ocrelizumab

KW - race

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=85129550175&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2022.103830

DO - 10.1016/j.msard.2022.103830

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 35490448

AN - SCOPUS:85129550175

SN - 2211-0348

VL - 63

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 103830

ER -

Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this